The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers
Open accessAbstract
CD133/prominin-1 is a pentaspan transmembrane glycoprotein overexpressed in various solid tumours including colorectal and glioblastomas. CD133 was found here to be highly expressed in >or=50% of pancreatic, gastric and intrahepatic cholangiocarcinomas. Quantitative flow cytometric analysis showed that a panel of established hepatocellular, pancreatic and gastric cancer cell lines expressed CD133 at levels higher than normal epithelial cells or bone marrow progenitor cells. A murine anti-human CD133 antibody (AC133) conjugated to a potent cytotoxic drug, monomethyl auristatin F (MMAF), effectively inhibited the growth of Hep3B hepatocellular and KATO III gastric cancer cells in vitro with IC(50) values of 2-7 ng ml(-1). MMAF induced apoptosis in the cancer cells as measured by caspase activation. The anti-CD133-drug conjugate (AC133-vcMMAF) was shown to internalise and colocalised with the lysosomal marker CD107a in the sensitive cell lines. In contrast, in the resistant cell line Su.86.86, the conjugate internalised and colocalised with the caveolae marker, Cav-1. Addition of ammonium chloride, an inhibitor of lysosomal trafficking and processing, suppressed the cytotoxic effect of AC133-vcMMAF in both Hep3B and KATO III. Anti-CD133-drug conjugate treatment resulted in significant delay of Hep3B tumour growth in SCID mice. Anti-CD133 antibody-drug conjugates warrant further evaluation as a therapeutic strategy to eradicate CD133+ tumours.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., & Thun, M. J. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0010 · Cited by 10,188
Identification of human brain tumour initiating cells
Singh, S. K., Hawkins, C., Clarke, I. D., Squire, J. A., Bayani, J., Hide, T., Henkelman, R. M., Cusimano, M. D., & Dirks, P. B. (2004) · Nature · doi:10.1038/nature03128 · Cited by 7,433
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,379
Bonnet, D., & Dick, J. E. (1997) · Nature Medicine · doi:10.1038/nm0797-730 · Cited by 5,864
A human colon cancer cell capable of initiating tumour growth in immunodeficient mice
O’Brien, C. A., Pollett, A., Gallinger, S., & Dick, J. E. (2007) · Nature · doi:10.1038/nature05372 · Cited by 4,087
Identification and expansion of human colon-cancer-initiating cells
Ricci-Vitiani, L., Lombardi, D. G., Pilozzi, E., Biffoni, M., Todaro, M., Peschle, C., & De Maria, R. (2007) · Nature · doi:10.1038/nature05384 · Cited by 3,998
Clarke, M. F., Dick, J. E., Dirks, P. B., Eaves, C. J., Jamieson, C. H. M., Jones, D. L., Visvader, J., Weissman, I. L., & Wahl, G. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-3126 · Cited by 3,051
Hermann, P. C., Huber, S. L., Herrler, T., Aicher, A., Ellwart, J. W., Guba, M., Bruns, C. J., & Heeschen, C. (2007) · Cell Stem Cell · doi:10.1016/j.stem.2007.06.002 · Cited by 2,897
Prospective Identification of Tumorigenic Prostate Cancer Stem Cells
Collins, A. T., Berry, P. A., Hyde, C., Stower, M. J., & Maitland, N. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2018 · Cited by 2,820
AC133, a Novel Marker for Human Hematopoietic Stem and Progenitor Cells
Yin, A. H., Miraglia, S., Zanjani, E. D., Almeida-Porada, G., Ogawa, M., Leary, A. G., Olweus, J., Kearney, J., & Buck, D. W. (1997) · Blood · doi:10.1182/blood.v90.12.5002 · Cited by 1,822
Cited by
Cancer stem cells: Role in tumor growth, recurrence, metastasis, and treatment resistance
Chang, J. C. (2016) · Medicine · doi:10.1097/md.0000000000004766 · Cited by 435
Dark force rising: Reawakening and targeting of fetal-like stem cells in colorectal cancer
Fey, S. K., Vaquero-Siguero, N., & Jackstadt, R. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114270 · Cited by 32
Metadata
- Authors
- Smith, L. M., Nesterova, A., Ryan, M. C., Duniho, S., Jonas, M., Anderson, M., Zabinski, R. F., Sutherland, M. K., Gerber, H.-P., Van Orden, K. L., Moore, P. A., Ruben, S. M., & Carter, P. J.
- Venue
- British Journal of Cancer
- Published
- 2008-06-10
- Volume
- 99
- Issue
- 1
- Pages
- 100-109
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2088635881
- Cited by
- 286
- References
- 39
- FWCI
- 11.95
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. https://app.cochat.ai/papers/10.1038/sj.bjc.6604437
- The paper
- Smith, L. M., Nesterova, A., Ryan, M. C., Duniho, S., Jonas, M., Anderson, M., Zabinski, R. F., Sutherland, M. K., Gerber, H.-P., Van Orden, K. L., Moore, P. A., Ruben, S. M., & Carter, P. J. (2008). CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6604437
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
